Your session is about to expire
← Back to Search
Phase 1 for Solid Tumors
Study Summary
This trial is testing a new drug called 23ME-01473 in patients with advanced solid cancers who have not responded well to standard treatments. The study aims to assess the safety, how well the
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Which individuals are eligible to participate in this clinical research study?
"To be eligible for this study, individuals must have solid neoplasms and fall within the age range of 18 to 110 years. The trial aims to recruit approximately 82 participants."
What is the collective count of participants who are joining this medical research study?
"Affirmative. Information on clinicaltrials.gov reveals that this trial is currently seeking volunteers. The study was first listed on March 7th, 2024, and most recently revised on March 21st, 2024. Researchers aim to recruit 82 participants from a single site."
Are there ongoing efforts to actively enroll participants for this clinical trial?
"As per clinicaltrials.gov, this research endeavor is actively in search of eligible candidates. The study's initial posting was on March 7th, 2024, and the most recent revision took place on March 21st of the same year."
Does this research include individuals aged 40 and above?
"Participants must be aged between 18 to 110 years old to meet the eligibility criteria for this research study. It is noteworthy that there are a total of 342 trials catering specifically to individuals under 18 and another set of 2576 aimed at those over the age of 65."
Share this study with friends
Copy Link
Messenger